How should a clinician discuss antipsychotic treatment with parents who refuse it for their child despite indications such as severe aggression, psychotic symptoms, or risk of self‑injury?

Approaching Parents Who Refuse Antipsychotics for Their Child

When a child presents with severe aggression, psychotic symptoms, or risk of self-injury, you must clearly communicate that delaying antipsychotic treatment is not appropriate when the risks involve readily manageable side effects compared to the serious consequences of untreated symptoms. 1

Frame the Urgency and Context

Confidently provide information about risks and benefits, then contextualize the urgency: Is this a situation where delay is acceptable, or does the severity demand immediate action? 1

• For a child with severe aggression, active psychosis, or imminent self-injury risk, it is not appropriate for parents to delay pharmacological treatment due to concerns about manageable side effects. 1
• Contrast this with less urgent scenarios (e.g., mild symptoms with good coping) where psychotherapy trials or deliberation time may be reasonable. 1
• Make explicit that the goal is to determine if their child responds to medication during an acute trial—most side effects (stomachaches, sedation, insomnia) resolve with dose adjustment or discontinuation and have little lasting significance. 1

Provide Comprehensive, Honest Education

Address both common risks and patient-specific vulnerabilities without minimizing or exaggerating either benefits or harms—this preserves trust and the therapeutic relationship. 1

• Discuss common and expectable risks (e.g., sedation, weight gain, metabolic changes) alongside patient-specific risks (e.g., heightened risk of antipsychotic-induced weight gain in an obese child with family history of type 2 diabetes). 1
• Address rare but clinically important adverse events (e.g., extrapyramidal symptoms, metabolic syndrome, potential for sudden cardiac events) while emphasizing that most acute-phase side effects are reversible. 1
• Directly address media controversies and parental fears about psychotropic medications in children, as families often arrive with misinformation from popular media. 1
• Reassure parents that you will discontinue medications that prove ineffective or cause unacceptable side effects—this increases comfort with initiating treatment. 1

Explore and Address Underlying Attitudes

Extended psychoeducation targeting specific attitudinal barriers may be necessary before some families can effectively implement treatment. 1

• Some families don't conceptualize their child's difficulties from a psychopharmacological perspective (e.g., "He doesn't need medication, he just won't listen"). 1
• Parents may fear psychotropic agents more than other medications (80% in one study) and believe psychotherapy alone suffices even for severe conditions like childhood schizophrenia. 2
• Negative attitudes about medication and concerns about addiction, dependency, or making the child "different but not better" must be addressed directly. 1, 2, 3
• Parents' educational level correlates with beliefs about addiction risk—tailor your discussion accordingly. 2

Clarify Roles, Responsibilities, and Monitoring

Be explicit about who monitors adherence, benefits, and side effects, and what your role encompasses (medication management only vs. comprehensive care). 1

• Parents are ultimately responsible for safe medication storage, monitoring adherence, and tracking benefits/side effects. 1
• Empower the child to identify and communicate medication effects. 1
• Clarify whether you provide medication management only, combined medication and psychotherapy, or consultation—families may expect more comprehensive involvement than you offer. 1
• Establish clear assessment strategies (self-report, parent report, teacher report) and a plan if the child doesn't respond as expected. 1

Emphasize the Trial Nature and Shared Decision-Making

Frame the acute phase as determining whether the child responds, with the decision to continue into maintenance phase made jointly after observing actual benefit versus side effects. 1

• At the end of a successful short-term trial, parents weigh observed medication benefit against actual acute side effects and potential longer-term risks—not hypothetical fears. 1
• Explain that some children respond well, others not at all, and that inadequate trials (too low dose, too short duration) risk labeling the child a "nonresponder" inappropriately. 1
• Provide information about alternative treatments and their respective benefits/risks, including both medication and psychosocial options. 1

Common Pitfalls to Avoid

• Never emphasize benefits while minimizing risks to enhance agreement—this violates good clinical care and damages the prescriber-patient relationship if significant adverse effects occur. 1
• Don't allow inadequate discussion of side effects—insufficient detail harms trust when problems arise. 1
• Avoid bargaining or deception—these undermine the therapeutic alliance. 4
• Don't implement medication-only plans when psychosocial needs remain unaddressed—this risks medicating problems better addressed through psychosocial intervention. 1

When Parental Refusal Persists

If parents continue to refuse despite thorough education and the child faces serious risk:

• Document the severity of symptoms, risks of non-treatment, and your clinical recommendation clearly. 1
• Consider whether consultation with ethics committees or multidisciplinary groups may help resolve the impasse in non-emergency situations. 5
• In emergency situations with acute agitation or danger, benzodiazepines or antipsychotics may be administered for immediate safety while continuing discussions. 4
• Recognize that while parental autonomy is important, the child's best interests—including medical and non-medical considerations—remain primary. 5